FDA Approves Cabometyx for First-Line Treatment of Advanced RCC
Treatment with cabozantinib led to a clinically meaningful improvement in progression-free survival compared with sunitinib.
Diagnosis & Disease Information
Cytoreductive Nephrectomy Benefits for Metastatic RCC Demonstrated
Patients who underwent cytoreductive nephrectomy for metastatic non-clear cell renal cell carcinoma had a significantly decreased risk of cancer-related mortality.
Kidney Cancer Bone Metastasis Predictors Id’d
Levels of alkaline phosphatase, calcium, and hemoglobin can independently predict bone metastasis in patients with renal cell carcinoma, Chinese investigators report.
Cytoreductive Nephrectomy Improves Survival in mRCC
Propensity score matching showed a 5.8 month survival advantage for initial CN vs initial systematic therapy.
FDA Approves Sunitinib for Adjuvant Treatment of RCC
At 5 years, 59.3% of patients treated with sunitinib were free from recurrence versus 51.3% who received placebo.
Blood Transfusion Predicts Worse Outcomes After Nephrectomy for RCC
Perioperative blood transfusion is associated with increased risks of tumor recurrence, metastatic progression, and cancer-related mortality.
RCC Subtypes Affect Post-Surgery Cancer-Related Mortality Risk
Patients with papillary versus clear cell renal cell carcinoma have a 24% decreased risk of dying from their cancer.
Immunotherapy Superior to Sunitinib for Front-Line mRCC Treatment
Checkpoint inhibitor combination of nivolumab plus ipilimumab improved progression-free and overall survival compared with sunitinib.
Upfront Cabozantinib for Advanced RCC Improves Outcomes
Cabozantinib reduced the risk of disease progression or death compared with sunitinib among patients with previously untreated advanced renal cell carcinoma.
Early NLR Changes Predict mRCC Immunotherapy Outcomes
Rises and decreases in neutrophil-to-lymphocyte ratio at 6 weeks after treatment with anti-PD-1/PD-L1 immune checkpoint blockade is associated with progression-free and overall survival.
- Loading...
Loading...
Loading... 
Loading...